| 000 | 01823 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518001400.0 | ||
| 264 | 0 | _c20190320 | |
| 008 | 201903s 0 0 eng d | ||
| 022 | _a1179-1888 | ||
| 024 | 7 |
_a10.1007/s40257-018-0388-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSingh, Sanminder | |
| 245 | 0 | 0 |
_aEffect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). _h[electronic resource] |
| 260 |
_bAmerican journal of clinical dermatology _cDec 2018 |
||
| 300 |
_a879-886 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Observational Study | ||
| 650 | 0 | 4 |
_aAdalimumab _xtherapeutic use |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge of Onset |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBiological Products _xtherapeutic use |
| 650 | 0 | 4 |
_aDermatologic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aEtanercept _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfliximab _xtherapeutic use |
| 650 | 0 | 4 | _aLongitudinal Studies |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethotrexate _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPsoriasis _xdiagnosis |
| 650 | 0 | 4 |
_aRegistries _xstatistics & numerical data |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUstekinumab _xtherapeutic use |
| 700 | 1 | _aKalb, Robert E | |
| 700 | 1 | _ade Jong, Elke M G J | |
| 700 | 1 | _aShear, Neil H | |
| 700 | 1 | _aLebwohl, Mark | |
| 700 | 1 | _aLangholff, Wayne | |
| 700 | 1 | _aHopkins, Lori | |
| 700 | 1 | _aSrivastava, Bhaskar | |
| 700 | 1 | _aArmstrong, April W | |
| 773 | 0 |
_tAmerican journal of clinical dermatology _gvol. 19 _gno. 6 _gp. 879-886 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40257-018-0388-z _zAvailable from publisher's website |
| 999 |
_c28886345 _d28886345 |
||